Agenus Announces End-of-Phase-2 Meeting Outcomes, Announces Topline Interim Phase 2 Data For BOT/BAL; Agreement Reached With FDA On Phase 3 Dose For BOT/BAL Combination
Portfolio Pulse from Benzinga Newsdesk
Agenus announced the outcomes of its End-of-Phase-2 meeting and topline interim Phase 2 data for its BOT/BAL combination. The company has reached an agreement with the FDA on the Phase 3 dose for this combination.
July 18, 2024 | 11:07 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Agenus announced positive outcomes from its End-of-Phase-2 meeting and interim Phase 2 data for its BOT/BAL combination. The company has also reached an agreement with the FDA on the Phase 3 dose for this combination.
The positive outcomes from the End-of-Phase-2 meeting and the agreement with the FDA on the Phase 3 dose are significant milestones for Agenus. These developments are likely to boost investor confidence and positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100